2,4-Dihydroxy-3′-methoxy-4′-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K/akt/mTOR signaling pathway

References

• Brunelle JK, Letai A. 2009. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 122(Pt 4):437–441.
   PubMed Web of Science ®Google Scholar
• Chavda SJ, Yong K. 2017. Multiple myeloma. Br J Hosp Med (Lond)). 78(2):C21–C27.
   PubMed Web of Science ®Google Scholar
• Dai Y, Jin S, Li X, Wang D. 2017. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget. 3:1354–1368.
   Google Scholar
• Du W, Pang C, Xue Y, Zhang Q, Wei X. 2015. Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells. Oncol Lett. 10(5):3266–3270.
   Google Scholar
• Durusu Z, Hazal H, Heval A, Biber A, Gerekci S, Ezgi G, Can Q. 2017. Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. Leuk Res. 55:33–40.
   PubMed Web of Science ®Google Scholar
• Fritz E, Ludwig H, Kundi M. 1984. Prognostic relevance of cellular morphology in multiple myeloma. Blood. 63(5):1072–1079.
   PubMed Web of Science ®Google Scholar
• Fulda S. 2015. Targeting apoptosis for anticancer therapy. Semin Cancer Biol. 31:84–88.
   PubMed Web of Science ®Google Scholar
• Heikaus S, Berg VD, Kempf T, Mahotka C, Gabbert HE, Ramp U. 2008. HA14-1 is able to reconstitute the impaired mitochondrial pathway of apoptosis in renal cell carcinoma cell lines. Cell Oncol. 30(5):419–433.
   PubMed Web of Science ®Google Scholar
• Jiang X, Jiang H, Shen Z, Wang X. 2014. Activation of mitochondrial protease OMA1 by Bax and Bak promotes cytochrome c release during apoptosis. Proc Natl Acad Sci USA. 111(41):14782–14787.
   PubMed Web of Science ®Google Scholar
• Keppler-Noreuil KM, Parker VE, Darling TN, Martinez-Agosto JA. 2016. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet. 172(4):402–421.
   PubMed Web of Science ®Google Scholar
• Li J, Tang C, Li L, Li R, Fan Y. 2016. Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo. J Exp Cancer Res. 35:61–65.
   PubMed Web of Science ®Google Scholar
• Liu T-J, Koul D, LaFortune T, Tiao N, Shen RJ, Maira S-M, Garcia-Echevrria C, Yung WKA. 2009. NVP-BEZ235, A novel dual PI3K/mTOR inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 8(8):2204–2210.
   PubMed Web of Science ®Google Scholar
• Lkeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S. 2010. PI3K/p110 δ is a novel therapeutic target in multiple myeloma. Blood. 116:1640–1648.
   Google Scholar
• Long FY, Wang T, Jia P, Wang HF, Qing Y, Xiong TT, He MJ, Wang XL. 2017. Anti-tumor effects of atractylenolide-I on human ovarian cancer cells. Med Sci Monit. 23:571–579.
   PubMed Web of Science ®Google Scholar
• Luo HF, Zhang LP, Hu CQ. 2001. Five novel oligostilbenes from the roots of Caragana sinica. Tetrahedron. 57(23):4849–4854.
   Web of Science ®Google Scholar
• Meng QX, Niu Y, Niu XW, Roubin RH, Hanrahan JR. 2009. Ethnobotany, phytochemistry and pharmacology of the genus Caragana used in traditional Chinese medicine. J Ethnopharmacol. 124(3):350–368.
   PubMed Web of Science ®Google Scholar
• Moreau P, Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, Dreyling M. 2013. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24:133–139.
   PubMed Web of Science ®Google Scholar
• Niu X, Li Y, Li W, Hu H, Yao H, Li H, Mu Q. 2014. The anti-inflammatory effects of Caragana tangutica ethyl acetate extract. J Ethnopharmacol. 152(1):99–105.
   PubMed Web of Science ®Google Scholar
• Obeid LM, Linardic CM, Karolak LA, Hannun YA. 1993. Programmed cell death induced by ceramide. Science. 259(5102):1769–1771.
   PubMed Web of Science ®Google Scholar
• Peh J, Fan TM, Wycislo KL, Roth HS, Hergenrother PJ. 2016. The combination of vemurafenib and procaspase-3 activation is synergistic in mutant BRAF melanomas. Mol Cancer Ther. 15(8):1859–1869.
   PubMed Web of Science ®Google Scholar
• Peng W, Liu Y, Hu M, Zhang M, Yang J, Liang F, Huang Q, Wu CJ. 2019. Toona sinensis: a comprehensive review on its traditional usages, phytochemistry, pharmacology and toxicology. Rev Bras Farmacogn. 29(1):111–124.
   PubMedGoogle Scholar
• Porta C, Paglino C, Mosca A. 2014. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:64–94.
   PubMedGoogle Scholar
• Qiu YX, Piao HS. 2012. Study on anti-tumor activity of isoflavone and glycosides compounds from C. microphylla in vitro. West China J Pharm Sci. 27:43–44.
   Google Scholar
• Rajkumar SV. 2012. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 87(1):78–88.
   PubMed Web of Science ®Google Scholar
• Saha SK, Yin YF, Kim K, Yang GM, Dayem AA, Choi HY, Cho SG. 2017. Valproic acid induces endocytosis-mediated doxorubicin internalization and shows synergistic cytotoxic effects in hepatocellular carcinoma cells. Int J Mol Sci. 18(5):1048–1068.
   PubMed Web of Science ®Google Scholar
• Shi J, Chen B, Su ZH, Hu CQ. 2003. Studies on flavonoid constituents of Caragana intermedia. Yao Xue Xue Bao. 38(8):599–602.
   PubMedGoogle Scholar
• Shu WJ, Zhang JJ, An N, Shen M, Huang ZX, Li X. 2016. Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head. J Int Med Res. 44:1462–1473.
   PubMed Web of Science ®Google Scholar
• Su M, Pan L, Jia XY, Zhang T, Jia XG, Zou ZM. 2017. Study on chemical constituent and anti-tumor on C. pruinosa. China J Chin Mater Med. 14:56–60.
   Google Scholar
• Sun ZH, Chen B, Zhang S, Hu CQ. 2004. Four new eudesmanes from Caragana intermedia and their biological activities. J Nat Prod. 67(12):1975–1979.
   PubMed Web of Science ®Google Scholar
• Toocheck C, Pinkhas D. 2018. Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy. BMJ Case Rep. 2018:bcr-2017-223611.
   PubMedGoogle Scholar
• Vidya PR, Senthil MR, Maitreyi S, Ramalingam K, Karunagran D, Nagini S. 2010. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition. Eur J Pharmacol. 649:84–91.
   PubMed Web of Science ®Google Scholar
• Vijay R, Shaji K. 2018. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. Leuk Lymphoma. 11:12–23.
   Google Scholar
• Wu XY, Tian F, Su MH, Wu M, Huang Y, Hu LH, Jin L, Zhu XJ. 2018. BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway. Int Immunopharmacol. 64:24–32.
   PubMed Web of Science ®Google Scholar
• Yang L, Dan HC, Sun M, Liu Q, Sun X-M, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, et al. 2004. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64(13):4394–4399.
   PubMed Web of Science ®Google Scholar
• Zhang FH, Yan YL, Wang Y, Liu Z. 2016. Lactucin induces potent anti-cancer effects in HL-60 human leukemia cancer cells by inducing apoptosis and sub-G1 cell cycle arrest. Bangladesh J Pharmacol. 11(2):478–484.
   Web of Science ®Google Scholar
• Zhang L, Wang H, Zhu J, Xu J, Ding K. 2014. Mollugin induces tumor cell apoptosis and autophagy via the PI3K/AKT/mTOR/p70S6K and ERK signaling pathways. Biochem Biophys Res Commun. 450(1):247–254.
   PubMed Web of Science ®Google Scholar
• Zheng CJ, Wang L, Han T, Xin HL, Jiang YP, Pan L, Jia XG, Qin LP. 2016. Pruinosanones A–C, anti-inflammatory isoflavone derivatives from Caragana pruinosa. Sci Rep. 6(1):31743.
   PubMed Web of Science ®Google Scholar
• Zhou DW, Liu ZL, Ma YQ. 2005. The study on phytogeographical distribution and differentiation of Caragana Fabr., Leguminosae. Bull Botan Res. 25:471–487.
   Google Scholar